Skip to main content

Table 3 PDAC related therapeutic aptamers and aptamers-based drug delivery systems

From: Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma

Targeted therapy Target SELEX Preclinical model Name Chemistry Ref.
Inhibitor PAUF Protein Xenograft model P12FR2 RNA [50]
Gemcitabine EGFR Protein In vitro E07 RNA [56]
AS1411 on gold nanoparticles (AuNS) as inhibitors Nucleolin Designed Aptamer In vitro AS1411 DNA [61]
Doxorubicin; nanoparticles with Folic acid/AS1411 Nucleolin Designed Aptamer In vitro AS1411 DNA [64]
Doxorubicin CD71 Protein In vitro C2-min RNA [58]
5-Fluoro-2′-Deoxyuridine ALPPL-2 Cell In vitro SQ-2 RNA [65]
Triptolide Nucleolin Designed Aptamer Xenograft model AS1411 DNA [69]
C/EBPα -saRNA HPAC Cell Xenograft model P19/P1 RNA [55]
C/EBPα -saRNA CD71 Protein Mouse model of advanced PDAC TR14 RNA [54]
Gemcitabine or 5-fluorouracil (5-FU) HPAC Cell In vitro P19 RNA [66]
Inhibitor Vimentin Cell In vitro P15 RNA [53]
Inhibitor PD1 Protein In vitro XA-PD1–78 DNA [52]
PD-L1 XA-PDL1–82 DNA
Monomethyl auristatin E (MMAE) CD71 Protein In vitro Waz RNA [70]
EGFR1 E07
Camptothecin Tenascin-C Protein Xenograft mice GBI-10 DNA [95]
Gemcitabine Nucleolin Designed Aptamer Xenograft mice AS1411 DNA [63]
Doxorubicin CD71 Cell In vitro XQ-2d DNA [93]